Literature DB >> 21604975

Meningococcal serogroup B vaccines: will they live up to expectations?

Wendell D Zollinger, Jan T Poolman, Martin C J Maiden.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21604975      PMCID： PMC3985070          DOI： 10.1586/erv.11.41

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN： 1476-0584            Impact factor:   5.217


× No keyword cloud information.
  21 in total

1.  Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile.

Authors:  J W Tappero; R Lagos; A M Ballesteros; B Plikaytis; D Williams; J Dykes; L L Gheesling; G M Carlone; E A Høiby; J Holst; H Nøkleby; E Rosenqvist; G Sierra; C Campa; F Sotolongo; J Vega; J Garcia; P Herrera; J T Poolman; B A Perkins
Journal:  JAMA       Date:  1999-04-28       Impact factor: 56.272

2.  Distribution of surface protein variants among hyperinvasive meningococci: implications for vaccine design.

Authors:  Rachel Urwin; Joanne E Russell; Emily A L Thompson; Edward C Holmes; Ian M Feavers; Martin C J Maiden
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

3.  A universal vaccine for serogroup B meningococcus.

Authors:  Marzia M Giuliani; Jeannette Adu-Bobie; Maurizio Comanducci; Beatrice Aricò; Silvana Savino; Laura Santini; Brunella Brunelli; Stefania Bambini; Alessia Biolchi; Barbara Capecchi; Elena Cartocci; Laura Ciucchi; Federica Di Marcello; Francesca Ferlicca; Barbara Galli; Enrico Luzzi; Vega Masignani; Davide Serruto; Daniele Veggi; Mario Contorni; Maurizio Morandi; Alessandro Bartalesi; Vanda Cinotti; Donatella Mannucci; Francesca Titta; Elisa Ovidi; Jo Anne Welsch; Dan Granoff; Rino Rappuoli; Mariagrazia Pizza
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-06       Impact factor: 11.205

4.  Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway.

Authors:  G Bjune; E A Høiby; J K Grønnesby; O Arnesen; J H Fredriksen; A Halstensen; E Holten; A K Lindbak; H Nøkleby; E Rosenqvist
Journal:  Lancet       Date:  1991-11-02       Impact factor: 79.321

5.  Monoclonal antibodies against the 70-kilodalton iron-regulated protein of Neisseria meningitidis are bactericidal and strain specific.

Authors:  A Pettersson; B Kuipers; M Pelzer; E Verhagen; R H Tiesjema; J Tommassen; J T Poolman
Journal:  Infect Immun       Date:  1990-09       Impact factor: 3.441

6.  Immunogenicity and safety of three doses of a bivalent (B:4:p1.19,15 and B:4:p1.7-2,4) meningococcal outer membrane vesicle vaccine in healthy adolescents.

Authors:  Dominique Boutriau; Jan Poolman; Ray Borrow; Jamie Findlow; Javier Diez Domingo; Joan Puig-Barbera; José María Baldó; Victoria Planelles; Angels Jubert; Julia Colomer; Angel Gil; Karin Levie; Anne-Diane Kervyn; Vincent Weynants; Francisco Dominguez; Ramon Barberá; Franklin Sotolongo
Journal:  Clin Vaccine Immunol       Date:  2006-10-25

Review 7.  Serotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes.

Authors:  C E Frasch; W D Zollinger; J T Poolman
Journal:  Rev Infect Dis       Date:  1985 Jul-Aug

8.  Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins.

Authors:  K Cartwright; R Morris; H Rümke; A Fox; R Borrow; N Begg; P Richmond; J Poolman
Journal:  Vaccine       Date:  1999-06-04       Impact factor: 3.641

Review 9.  Molecular typing of meningococci: recommendations for target choice and nomenclature.

Authors:  Keith A Jolley; Carina Brehony; Martin C J Maiden
Journal:  FEMS Microbiol Rev       Date:  2006-12-01       Impact factor: 16.408

10.  Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba.

Authors:  G V Sierra; H C Campa; N M Varcacel; I L Garcia; P L Izquierdo; P F Sotolongo; G V Casanueva; C O Rico; C R Rodriguez; M H Terry
Journal:  NIPH Ann       Date:  1991-12
View more
  9 in total

1.  Refolding, purification and crystallization of the FrpB outer membrane iron transporter from Neisseria meningitidis.

Authors:  Muhammad Saleem; Stephen M Prince; Hema Patel; Hannah Chan; Ian M Feavers; Jeremy P Derrick
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2012-01-27

2.  Adjuvant efficacy of mOMV against avian influenza virus infection in mice.

Authors:  Byeong-Jae Lee; Sang-Ho Lee; Min-Suk Song; Philippe Noriel Q Pascua; Hyeok-il Kwon; Su-Jin Park; Eun-Ha Kim; Arun Decano; Se Mi Kim; Gyo Jin Lim; Doo-Jin Kim; Kyu-Tae Chang; Sang-Hyun Kim; Young Ki Choi
Journal:  J Microbiol       Date:  2013-10-31       Impact factor: 3.422

3.  Capsular polysaccharide vaccine for Group B Neisseria meningitidis, Escherichia coli K1, and Pasteurella haemolytica A2.

Authors:  John B Robbins; Rachel Schneerson; Guilin Xie; Lars Å Hanson; Lars Åke-Hanson; Mark A Miller
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-24       Impact factor: 11.205

4.  Persistence of antibodies in adolescents 18-24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine.

Authors:  Maria Elena Santolaya; Miguel O'Ryan; María Teresa Valenzuela; Valeria Prado; Rodrigo F Vergara; Alma Muñoz; Daniela Toneatto; Gabriela Graña; Huajun Wang; Peter M Dull
Journal:  Hum Vaccin Immunother       Date:  2013-06-28       Impact factor: 3.452

5.  Improved production process for native outer membrane vesicle vaccine against Neisseria meningitidis.

Authors:  Bas van de Waterbeemd; Gijsbert Zomer; Patricia Kaaijk; Nicole Ruiterkamp; René H Wijffels; Germie P J M van den Dobbelsteen; Leo A van der Pol
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

Review 6.  A multi-component meningococcal serogroup B vaccine (4CMenB): the clinical development program.

Authors:  Miguel O'Ryan; Jeffrey Stoddard; Daniela Toneatto; James Wassil; Peter M Dull
Journal:  Drugs       Date:  2014-01       Impact factor: 9.546

Review 7.  Meningococcal B vaccine and the vision of a meningitis free world.

Authors:  A Bianchi; S Fantoni; A Prugnola
Journal:  J Prev Med Hyg       Date:  2015-08-31

8.  Use of a molecular decoy to segregate transport from antigenicity in the FrpB iron transporter from Neisseria meningitidis.

Authors:  Muhammad Saleem; Stephen M Prince; Stephen E J Rigby; Muhammad Imran; Hema Patel; Hannah Chan; Holly Sanders; Martin C J Maiden; Ian M Feavers; Jeremy P Derrick
Journal:  PLoS One       Date:  2013-02-15       Impact factor: 3.240

9.  Cysteine depletion causes oxidative stress and triggers outer membrane vesicle release by Neisseria meningitidis; implications for vaccine development.

Authors:  Bas van de Waterbeemd; Gijsbert Zomer; Jan van den Ijssel; Lonneke van Keulen; Michel H Eppink; Peter van der Ley; Leo A van der Pol
Journal:  PLoS One       Date:  2013-01-23       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.